418 related articles for article (PubMed ID: 9815853)
21. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
22. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Kunz C; Borghouts C; Buerger C; Groner B
Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
[TBL] [Abstract][Full Text] [Related]
23. Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
Shimizu H; Seiki T; Asada M; Yoshimatsu K; Koyama N
Oncogene; 2003 Feb; 22(6):831-9. PubMed ID: 12584562
[TBL] [Abstract][Full Text] [Related]
24. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
25. Induction or suppression of expression of cytochrome C oxidase subunit II by heregulin beta 1 in human mammary epithelial cells is dependent on the levels of ErbB2 expression.
Sun Y; Lin H; Zhu Y; Ma C; Ye J; Luo J
J Cell Physiol; 2002 Aug; 192(2):225-33. PubMed ID: 12115729
[TBL] [Abstract][Full Text] [Related]
26. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
el-A Helal T; Khalifa A; Kamel AS
Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
[TBL] [Abstract][Full Text] [Related]
28. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
Kim KK; Lee JJ; Yang Y; You KH; Lee JH
Carcinogenesis; 2008 Apr; 29(4):704-12. PubMed ID: 18258606
[TBL] [Abstract][Full Text] [Related]
29. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins.
Miller P; DiOrio C; Moyer M; Schnur RC; Bruskin A; Cullen W; Moyer JD
Cancer Res; 1994 May; 54(10):2724-30. PubMed ID: 7909494
[TBL] [Abstract][Full Text] [Related]
30. [Overexpression of c-erbB-2 gene product is associated with poor prognosis factors in breast carcinoma].
Cianga C; Cianga P; Cozma L; Diaconu C; Carasevici E
Rev Med Chir Soc Med Nat Iasi; 2003; 107(2):349-53. PubMed ID: 14755939
[TBL] [Abstract][Full Text] [Related]
31. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
Schaefer G; Fitzpatrick VD; Sliwkowski MX
Oncogene; 1997 Sep; 15(12):1385-94. PubMed ID: 9333014
[TBL] [Abstract][Full Text] [Related]
32. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells.
Fiucci G; Ravid D; Reich R; Liscovitch M
Oncogene; 2002 Apr; 21(15):2365-75. PubMed ID: 11948420
[TBL] [Abstract][Full Text] [Related]
33. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
Ram TG; Hosick HL; Ethier SP
J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
[TBL] [Abstract][Full Text] [Related]
34. Suppression of metastatic potential of high-metastatic Lewis lung carcinoma cells by vanadate, an inhibitor of tyrosine phosphatase, through inhibiting cell-substrate adhesion.
Takenaga K
Invasion Metastasis; 1996; 16(2):97-106. PubMed ID: 9030244
[TBL] [Abstract][Full Text] [Related]
35. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells.
Zhu XF; Wang JS; Cai LL; Zeng YX; Yang D
Cancer Sci; 2006 Jan; 97(1):84-9. PubMed ID: 16367926
[TBL] [Abstract][Full Text] [Related]
36. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
37. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
38. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.
Deshane J; Loechel F; Conry RM; Siegal GP; King CR; Curiel DT
Gene Ther; 1994 Sep; 1(5):332-7. PubMed ID: 7584099
[TBL] [Abstract][Full Text] [Related]
39. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
Lim SJ; Lopez-Berestein G; Hung MC; Lupu R; Tari AM
Oncogene; 2000 Dec; 19(54):6271-6. PubMed ID: 11175341
[TBL] [Abstract][Full Text] [Related]
40. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
DiGiovanna MP; Stern DF
Cancer Res; 1995 May; 55(9):1946-55. PubMed ID: 7728765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]